Peri-Coronary Adipose Tissue Is a Predictor of Stent Failure in Patients Undergoing Percutaneous Coronary Intervention.


Journal

Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551

Informations de publication

Date de publication:
08 2023
Historique:
received: 05 12 2022
revised: 20 02 2023
accepted: 22 02 2023
medline: 14 8 2023
pubmed: 3 3 2023
entrez: 2 3 2023
Statut: ppublish

Résumé

Coronary inflammation is postulated as a driver of atherosclerosis and dysfunctional arterial healing which may trigger stent failure. Pericoronary adipose tissue (PCAT) attenuation, detected on computer tomography coronary angiography (CTCA), is an emerging non-invasive marker of coronary inflammation. This propensity matched study assessed the utility of both lesion specific (PCAT Patients undergoing CTCA assessment for coronary artery disease with subsequent stent insertion within 60 days and repeat coronary angiography for any clinical reason within 5 years were included in the study. Stent failure was defined as binary restenosis of >50 % on quantitative coronary angiography analysis or stent thrombosis. Both PCAT One hundred and fifty-one patients met inclusion criteria. Of these, 26 (17.2 %) had study-defined failure. A significant difference in PCAT Patients with stent failure exhibit significantly increased PCAT

Identifiants

pubmed: 36863976
pii: S1553-8389(23)00078-7
doi: 10.1016/j.carrev.2023.02.022
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

61-66

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest All authors report no conflict of interest.

Auteurs

Jason Nogic (J)

Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Melbourne, Australia. Electronic address: jnogic@gmail.com.

Jiwon Kim (J)

Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Melbourne, Australia.

Jamie Layland (J)

Cardiology, Department of Medicine, Peninsula Health, Peninsula Clinical School, Central Clinical School, Monash University, Melbourne, Victoria, Australia.

Kevin Cheng (K)

Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Melbourne, Australia.

Damini Dey (D)

Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States of America.

Dennis T Wong (DT)

Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Melbourne, Australia.

James D Cameron (JD)

Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Melbourne, Australia.

Adam J Brown (AJ)

Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH